25N-NBOMe - PsychonautWiki

25N-NBOMe

Skull and crossbones darktextred2.png

Members of the NBOMe series have been linked to numerous overdoses and fatalities.[1][2][3]

It is strongly discouraged to insufflate (snort) or take higher doses of these compounds. Please see this section for more details.

Summary sheet: 25N-NBOMe
25N-NBOMe
25N-NBOMe.svg
Chemical Nomenclature
Common names 25N-NBOMe
Systematic name 2-(2,5-dimethoxy-4-nitrophenyl)-N-(2-methoxybenzyl)ethanamine
Class Membership
Psychoactive class Psychedelic
Chemical class Phenethylamine
Routes of Administration

WARNING: Always start with lower doses due to differences between individual body weight, tolerance, metabolism, and personal sensitivity. See responsible use section.





Sublingual
Dosage
Threshold < 100 µg
Light 100 - 300 µg
Common 300 - 800 µg
Strong 800 - 1300 μg
Heavy The NBOMe series can be fatal at heavy doses.[1][2][3]
Duration
Total 5 - 10 hours
Onset 45 - 75 minutes
Peak 2 - 3 hours
Offset 2 - 3 hours
After effects 5 - 10 hours
Insufflated
Dosage
Heavy The NBOMe series can be fatal when insufflated.[1][2][3] It is strongly discouraged.
Duration
Total 4 - 8 hours






DISCLAIMER: PW's dosage information is gathered from users and resources for educational purposes only. It is not a recommendation and should be verified with other sources for accuracy.

Interactions
2C-T-X
5-MeO-xxt
Caffeine
Cannabis
DOx
MAOIs
MDMA
MXE
Amphetamines
aMT
Cocaine
DXM
Tramadol
Lithium


25N-NBOMe (also known as 2C-N-NBOMe, NBOMe-2C-N and N-Bomb, although this term is used broadly to refer to the entire 25x-NBOMe family) is a novel psychedelic substance of the phenethylamine chemical class that produces stimulating psychedelic effects when administered.

The name 25N-NBOMe, which short-hand for 2C-N-NBOMe, is a derivative of the phenethylamine psychedelic 2C-N. It was discovered in 2004 by Ralf Heim at the Free University of Berlin[4] and subsequently investigated by a team at Purdue University led by David E. Nichols.[5]

25N-NBOMe has a notably shorter duration than the rest of the 25x-NBOMe series with a total duration of 6 hours and a peak duration of 2 hours.[6] It is moderately active at a dose of one milligram, and two milligrams provide a strong/heavy trip.[7] This substance is considerably less potent when compared to the more popular NBOMe compunds such as 25B-NBOMe, 25I-NBOMe and 25C-NBOMe, all which produce strong experiences at doses above 1mg.[citation needed] Compounds of the NBOMe family are not orally active and should be administered sublingually by placing and holding it into one's mouth and allowing it to absorb over a period of 15-25 minutes.

This substance had no history of human use before being sold online as a designer drug in 2010.[citation needed] Extremely little is known about the pharmacological properties, metabolism, and toxicity of 25N-NBOMe in humans, and many members of the 25x-NBOMe series have been associated with deaths and hospitalizations. Along with its highly sensitive dose-response and unpredictable effects, many reports also suggest that this substance may be overly difficult to use safely. Therefore it is highly advised to approach this poorly understood psychedelic substance with the proper amount of precaution and harm reduction practices if using it.

Chemistry

25N-NBOMe or 2C-N-NBOMe is a serotonergic N-benzyl derivative of the substituted phenethylamine psychedelic known as 2C-N. 25N-NBOMe is a substituted phenethylamine with methoxy groups CH3O- attached to carbons R2 and R5 as well as a nitro group NO2- attached to carbon R4. It differs from 2C-N structurally through a substitution on the amine (NH2) with a 2-methoxybenzyl (BOMe) group as shown in the image to the right. 25N-NBOMe shares this 2-methoxybenzyl substitution with other chemicals of the NBOMe family. This NBOMe addition contains a methoxy ether CH3O- bound to a benzene ring at R2.

Pharmacology

Further information: Serotonergic psychedelic

25N-NBOMe likely has efficacy at the 5-HT2A receptor where it is assumed to act as a partial agonist. However, the role of these interactions and how they result in the psychedelic experience continues to remain elusive.

There is insufficient scientific research to determine this compound's true nature as the pharmacological properties of 25N-NBOMe have not been described in the scientific literature, but only in anecdotal reports.[8]

Subjective effects

Disclaimer: The effects listed below cite the Subjective Effect Index (SEI), an open research literature based on anecdotal user reports and the personal analyses of PsychonautWiki contributors. As a result, they should be viewed with a healthy degree of skepticism.

It is also worth noting that these effects will not necessarily occur in a predictable or reliable manner, although higher doses are more liable to induce the full spectrum of effects. Likewise, adverse effects become increasingly likely with higher doses and may include addiction, severe injury, or death ☠.

Physical effects
 

Visual effects
 

Cognitive effects
 

Multi-sensory effects
 

Transpersonal effects
 

Experience reports

There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:

Toxicity and harm potential

The toxicity and long-term health effects of recreational 25N-NBOMe use have not been studied in any scientific context and the exact toxic dosage is unknown. This is because 25N-NBOMe is a research chemical with very little history of human usage. Anecdotal evidence from people within the psychonaut community who have tried 25N-NBOMe suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed).

Users should be very careful and consider that ingesting 2mg+ of NBOMe series chemicals have proven fatal in some cases. Although there are no reported deaths caused by 25N-NBOMe at this time, it is a rare research chemical with very little history of human usage and is therefore potentially fatal at heavy dosages.

It is strongly recommended that one use harm reduction practices when using this drug.

Tolerance and addiction potential

25N-NBOMe is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.

Tolerance to the effects of 25N-NBOMe is built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). 25N-NBOMe presents cross-tolerance with all psychedelics, meaning that after the consumption of 25N-NBOMe all psychedelics will have a reduced effect.

Overdose

Due to the very high potency and seemingly unpredictable effects the margin between a normal and an overdose of NBOMe compounds is extremely small when compared to many other substances. The exact toxic dose is unclear since it seems to depend a lot on personal physiology, rather than predominantly dose. However, various anecdotal reports suggest that dangerous side effects begin to appear when exceeding 1000 μg and it possibly becoming lethal for the more sensitive people at roughly 2000 μg. Reports of other people surviving much higher doses, sometimes even without any major side effects have been documented as well.

There is also the uncertainty of dosage on blotter paper since it is rather difficult to lay such an exact dosage. Insufflating, vaporizing or drinking tinctures of this substance is highly discouraged because of this and has been tied to many documented deaths[1][2][3]. One study found that 25I‐NBOMe and 25C‐NBOMe blotter papers contained 'hotspots' with higher quantities of the drug, implying an inherent risk of overdosing.[9]

The overdose effects of NBOMes are typically a dangerously high heart rate, blood pressure, hyperthermia and significant vasoconstriction[10][11] also accompanied by confusion, delusions, panic attacks, aggressive behavior, numbness or pain, amnesia and often seizures. The risks in an overdose include anything from organ failure to cardiac arrest and death[citation needed]. There are also multiple reports of people lethally injuring themselves or falling to death[12][13]. Benzodiazepines or antipsychotics can help with the psychological effects during an overdose although medical attention should always be called in even a possible overdose of 25I-NBOMe.

Dangerous interactions

Warning: Many psychoactive substances that are reasonably safe to use on their own can suddenly become dangerous and even life-threatening when combined with certain other substances. The following list provides some known dangerous interactions (although it is not guaranteed to include all of them).

Always conduct independent research (e.g. Google, DuckDuckGo, PubMed) to ensure that a combination of two or more substances is safe to consume. Some of the listed interactions have been sourced from TripSit. Due to the highly unpredictable nature of the NBOMe series, it is generally advised to avoid mixing them with other psychoactive substances.

  • 2C-T-X - The 2C-T-X phenethylamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. As a result, this combination should be avoided.
  • 5-MeO-xxt - The 5-MeO tryptamines can be unpredictable in their interactions and the NBOMes are known to be unpredictable even alone. As a result, this combination should be avoided.
  • Amphetamines - Amphetamines and NBOMes both provide considerable stimulation. When combined they can result in tachycardia, hypertension, vasoconstriction and, in extreme cases, heart failure. The anxiogenic and focusing effects of stimulants are also not good in combination with psychedelics as they can lead to unpleasant thought loops. NBOMes are known to cause seizures and stimulants can increase this risk.
  • aMT
  • Caffeine - Caffeine can bring out the natural stimulation from psychedelic drugs to make it uncomfortable. High doses can cause anxiety which is hard to handle while tripping.
  • Cannabis - Cannabis has an unexpectedly strong and unpredictable synergy with the effects of psychedelics. Caution is advised with this combination as it can significantly increase the risk of adverse psychological reactions like anxiety, paranoia, panic attacks, and psychosis. Users are advised to start off with only a fraction of their normal cannabis dose and take long breaks between hits to avoid over intake.
  • Cocaine - Cocaine and NBOMes both provide considerable stimulation. When combined they can result in severe vasoconstriction, tachycardia, hypertension, and in extreme cases heart failure.
  • DOx
  • DXM
  • Lithium - Lithium is commonly prescribed in the treatment of [https://en.wikipedia.org/wiki/Bipolar_disorder bipolar disorder. There is a large body of anecdotal evidence that suggests taking it with psychedelics significantly increases the risk of psychosis and seizures. As a result, this combination is strictly discouraged.
  • MAOIs - MAO-B inhibitors can increase the potency and duration of phenethylamines unpredictably.
  • MDMA
  • MXE - As an NMDA antagonist, MXE potentiates NBOMes which can be unpleasantly intense.
  • Tramadol - Tramadol is well known to lower seizure threshold and NBOMes have also shown a tendency to cause severe seizures

Legal status

 

This legality section is a stub.

As such, it may contain incomplete or wrong information. You can help by expanding it.

  • Austria: 25N-NBOMe is illegal to possess, produce and sell under the NPSG (Neue-Psychoaktive-Substanzen-Gesetz Österreich).[citation needed]
  • Brazil: Possession, production and sale is illegal as it is listed on Portaria SVS/MS nº 344.[14]
  • Germany: 25N-NBOMe is controlled under Anlage I BtMG (Narcotics Act, Schedule I) as of June 9, 2016.[15][16] It is illegal to manufacture, possess, import, export, buy, sell, procure or dispense it without a license.[17]
  • Latvia: 25N-NBOMe is a Schedule I controlled substance.[18]
  • Switzerland: 25N-NBOMe is a controlled substance specifically named under Verzeichnis E.[19]
  • United Kingdom: 25N-NBOMe is a Class A drug in the United Kingdom as a result of the N-benzylphenethylamine catch-all clause.[20]
  • United States: 25N-NBOMe is unscheduled in the United States. It may be considered an analogue of 2C-N (which is a Schedule I drug under the Controlled Substances Act). As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.

See also

External links

References

  1. 1.0 1.1 1.2 1.3 Erowid 25I-NBOMe (2C-I-NBOMe) Vault : Fatalities / Deaths 
  2. 2.0 2.1 2.2 2.3 Erowid 2C-C-NBOMe (25C-NBOMe) Vault : Fatalities / Deaths 
  3. 3.0 3.1 3.2 3.3 Erowid NBOMe (Other or Unknown NBOMe-Compound) Vault : Fatalities / Deaths 
  4. Heim, R. (2004). "Synthese und Pharmakologie potenter 5-HT2A-Rezeptoragonisten mit N-2 -Methoxybenzyl-Partialstruktur: Entwicklung eines neuen Struktur-Wirkungskonzepts". doi:10.17169/refubium-16193. 
  5. Braden, M. R. (1 January 2007). "Towards a biophysical understanding of hallucinogen action". Theses and Dissertations Available from ProQuest: 1–176. Retrieved 8 August 2012. 
  6. http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread
  7. https://www.drugs-forum.com/forum/showthread.php?t=249067
  8. The Big & Dandy 25N-NBOMe Thread | http://www.bluelight.org/vb/threads/539694-The-Big-amp-Dandy-25N-NBOMe-Thread
  9. Lützen, E., Holtkamp, M., Stamme, I., Schmid, R., Sperling, M., Pütz, M., Karst, U. (April 2020). "Multimodal imaging of hallucinogens 25C‐ and 25I‐NBOMe on blotter papers". Drug Testing and Analysis. 12 (4): 465–471. doi:10.1002/dta.2751. ISSN 1942-7603. 
  10. Marchi, N. C., Scherer, J. N., Fara, L. S., Remy, L., Ornel, R., Reis, M., Zamboni, A., Paim, M., Fiorentin, T. R., Wayhs, C. A. Y., Von Diemen, L., Pechansky, F., Kessler, F. H. P., Limberger, R. P. (1 March 2019). "Clinical and Toxicological Profile of NBOMes: A Systematic Review". Psychosomatics. 60 (2): 129–138. doi:10.1016/j.psym.2018.11.002. ISSN 0033-3182. 
  11. Yoon, K. S., Yun, J., Kim, Y.-H., Shin, J., Kim, S. J., Seo, J.-W., Hyun, S.-A., Suh, S. K., Cha, H. J. (1 April 2019). "2-(2,5-Dimethoxy-4-methylphenyl)-N-(2-methoxybenzyl)ethanamine (25D-NBOMe) and N-(2-methoxybenzyl)-2,5-dimethoxy-4-chlorophenethylamine (25C-NBOMe) induce adverse cardiac effects in vitro and in vivo". Toxicology Letters. 304: 50–57. doi:10.1016/j.toxlet.2019.01.004. ISSN 0378-4274. 
  12. https://psychonautwiki.org/wiki/File:Nbome_death_news_i2013e0190_disp.jpg
  13. https://psychonautwiki.org/wiki/File:Nbome_death_news_i2013e0191_disp.jpg
  14. http://portal.anvisa.gov.br/documents/10181/3115436/%281%29RDC_130_2016_.pdf/fc7ea407-3ff5-4fc1-bcfe-2f37504d28b7
  15. "Einundreißigste Verordnung zur Änderung betäubungsmittelrechtlicher Vorschriften" (in German). Bundesanzeiger Verlag. Retrieved December 11, 2019. 
  16. "Anlage I BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  17. "§ 29 BtMG" (in German). Bundesministerium der Justiz und für Verbraucherschutz. Retrieved December 11, 2019. 
  18. Zaudējis spēku - Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem 
  19. "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Bundeskanzlei [Federal Chancellery of Switzerland]. Retrieved January 1, 2020. 
  20. The Misuse of Drugs Act 1971 (Ketamine etc.) (Amendment) Order 2014, London: The Stationery Office Limited., retrieved 5 July 2017